Global sales of Vytorin fell 18 percent, while sales of Zetia dropped by 12 percent in the third quarter. The loss of sales revenue from the two drugs, combined with difficult economic conditions worldwide, have led drug maker Merck to announce that it will cut its workforce by 12 percent.
